Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones

被引:3
作者
Drago, L
De Vecchi, E
Nicola, L
Valli, M
Marchetti, F
Gismondo, MR
机构
[1] Univ Milan, L Sacco Teaching Hosp, Dept Clin Sci, Lab Clin Microbiol, I-20122 Milan, Italy
[2] GlaxoSmithKline, Healthcare & Clin Res, Verona, Italy
关键词
Gram-positive bacteria; Gram-negative bacteria; levofloxacin; moxifloxacin; ciprofloxacin; norfloxacin;
D O I
10.1179/joc.2003.15.2.118
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The bactericidal activity of levofloxacin, ciprofloxacin, moxifloxacin and norfloxacin against clinical isolates conventionally classified as resistant to fluoroquinolones were compared at their maximum concentrations in serum, urine (except moxifloxacin) and bronchial mucosa (except norfloxacin). Time killing curves against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, and Streptococcus pneumoniae were performed. Serum concentrations of the tested drugs were not able to produce a bactericidal effect on fluoroquinolone-resistant strains. In the urine series, levofloxacin was always bactericidal (decrease greater than or equal to3 logs CFU/ml), while norfloxacin and ciprofloxacin were bactericidal on E. coli (both), P. mirabilis (norfloxacin) and P. aeruginosa (ciprofloxacin). In the bronchial mucosa series, S. pneumoniae was rapidly killed by levofloxacin and moxifloxacin, and K. pneumoniae by levofloxacin after 12 hours. In conclusion, the maximum levofloxacin concentrations achievable at certain body sites allowed killing even of strains defined as resistant by conventional breakpoints.
引用
收藏
页码:118 / 123
页数:6
相关论文
共 24 条
[1]   Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials [J].
Aminimanizani, A ;
Beringer, P ;
Jelliffe, R .
CLINICAL PHARMACOKINETICS, 2001, 40 (03) :169-187
[2]  
Balfour JAB, 1999, DRUGS, V57, P363
[3]  
Ball P, 2001, Semin Respir Infect, V16, P215, DOI 10.1053/srin.2001.25628
[4]   Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin [J].
Bauernfeind, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) :639-651
[5]  
BERGAN T, 1987, AM J MED, V82, P97
[6]   A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones' [J].
Blondeau, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :1-11
[7]  
DUSLEY MN, 1991, AM J MED A, V6, pS45
[8]  
*E LILL IT, OCT 400MG COMPR MOX
[9]   Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model:: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses [J].
Firsov, AA ;
Lubenko, IY ;
Vostrov, SN ;
Kononenko, OV ;
Zinner, SH ;
Portnoy, YA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) :725-732
[10]   The clinical pharmacokinetics of levofloxacin [J].
Fish, DN ;
Chow, AT .
CLINICAL PHARMACOKINETICS, 1997, 32 (02) :101-119